Compass Therapeutics Inc (CMPX) Stock Price, Quote & News

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8099

Website: www.compasstherapeutics.com

Address:

80 Guest Street, Suite 601, Boston, United States

Greenpa Sep. 7 at 11:05 AM

$DCTH $CMPX $VSTM — I own nice positions in these three oncology focused stocks that I believe have great return potential over the next several years. Each are leaders and I believe undervalued. However, I so often lose site of the human aspect of what these companies are doing to improve the lives of cancer victims and their families. Maybe I should be focused on that more important human aspect more frequently. Best to longs and also the families of those patients who are using and will regrettably need to use the tools and drugs being furnished by these companies.

0 · Reply

King_of_Bio Sep. 5 at 5:02 PM

$GOSS $AKBA $TSHA $SLS $CMPX Told you guys! $GOSS is flying under the radar and ripping, $TSHA same thing! It's BIO SEASON!

1 · Reply

King_of_Bio Sep. 3 at 1:04 PM

$CMPX 128% Year to date - damn good here!

0 · Reply

lexlut Sep. 2 at 1:52 PM

$CMPX https://finance.yahoo.com/news/piper-sandler-reaffirms-optimism-compass-045759757.html

0 · Reply

lexlut Aug. 29 at 1:43 PM

$CMPX Buy before it explodes 🍾

1 · Reply

redsstocktwits Aug. 28 at 7:43 PM

$CMPX Just 1 product slip into the market out of several CMPX pipeline THIS IS CAN BE A $100 plus stock... We are getting close to the finish line for CTX-009... If this reach the finish right after the Fed starting cutting interest rates THIS WILL BE ASTRONOMIC 😍😍😍🤑🤑🤑

0 · Reply

lexlut Aug. 28 at 4:03 PM

$OCGN $CMPX Stocks to buy

0 · Reply

lexlut Aug. 28 at 4:02 PM

$CMPX

0 · Reply

lexlut Aug. 28 at 1:54 PM

$CMPX

0 · Reply

lexlut Aug. 28 at 1:54 PM

$CMPX

0 · Reply

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 13, 2025, 9:40 AM EDT - 26 days ago

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Aug 12, 2025, 10:28 PM EDT - 26 days ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 4:01 PM EDT - 26 days ago

Compass Therapeutics Announces Proposed Public Offering

Aug 11, 2025, 7:00 AM EDT - 4 weeks ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2025, 4:01 PM EDT - 4 weeks ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

May 28, 2025, 8:00 AM EDT - 3 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 12, 2025, 9:51 PM EDT - 4 months ago

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

May 8, 2025, 8:00 AM EDT - 4 months ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 4 months ago

Compass Therapeutics to Participate in Upcoming May Investor Events

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 5 months ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 2, 2025, 4:05 PM EDT - 5 months ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 5 months ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Feb 27, 2025, 8:00 AM EST - 6 months ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Dec 10, 2024, 8:00 AM EST - 9 months ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 9, 2024, 12:54 PM EST - 9 months ago

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Dec 2, 2024, 8:00 AM EST - 10 months ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 10 months ago

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 12, 2024, 8:00 AM EST - 10 months ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2024, 10:05 AM EST - 10 months ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 1 year ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Jun 20, 2024, 3:14 AM EDT - 1 year ago

Compass Therapeutics: Pointing Right At Some Tough Cancers

May 28, 2024, 4:10 PM EDT - 1 year ago

Compass Therapeutics Announces CEO Transition

May 23, 2024, 5:05 PM EDT - 1 year ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 14, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 9, 2024, 12:00 PM EDT - 1 year ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Jan 5, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Provides Corporate Update

Nov 9, 2023, 7:30 AM EST - 1 year ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 22, 2023, 4:05 PM EDT - 2 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

May 4, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Apr 19, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 2, 2023, 8:30 AM EST - 2 years ago

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Jan 19, 2023, 5:00 PM EST - 2 years ago

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Jan 6, 2023, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Dec 15, 2022, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Dec 1, 2022, 8:30 AM EST - 3 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Nov 22, 2022, 8:00 AM EST - 3 years ago

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 9, 2022, 9:00 AM EST - 3 years ago

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 3 years ago

Compass Therapeutics to Present at Upcoming Investment Conferences

Greenpa Sep. 7 at 11:05 AM

0 · Reply

King_of_Bio Sep. 5 at 5:02 PM

$GOSS $AKBA $TSHA $SLS $CMPX Told you guys! $GOSS is flying under the radar and ripping, $TSHA same thing! It's BIO SEASON!

1 · Reply

King_of_Bio Sep. 3 at 1:04 PM

$CMPX 128% Year to date - damn good here!

0 · Reply

lexlut Sep. 2 at 1:52 PM

$CMPX https://finance.yahoo.com/news/piper-sandler-reaffirms-optimism-compass-045759757.html

0 · Reply

lexlut Aug. 29 at 1:43 PM

$CMPX Buy before it explodes 🍾

1 · Reply

redsstocktwits Aug. 28 at 7:43 PM

0 · Reply

lexlut Aug. 28 at 4:03 PM

$OCGN $CMPX Stocks to buy

0 · Reply

lexlut Aug. 28 at 4:02 PM

$CMPX

0 · Reply

lexlut Aug. 28 at 1:54 PM

$CMPX

0 · Reply

lexlut Aug. 28 at 1:54 PM

$CMPX

0 · Reply

King_of_Bio Aug. 28 at 1:45 PM

$CMPX $GOSS $TSHA $AKBA Bio stocks you rarely ever hear about that are doing VERY well and will make shareholders VERY wealthy in years to come. If you know, you know. Good luck all - it's ALWAYS bio season.

2 · Reply

BlueMoonTrading Aug. 27 at 10:47 PM

$CMPX Strong. Break $3.45 area and I think this one flies.

0 · Reply

outlawinvestor1 Aug. 26 at 12:42 PM

$CMPX I realize this happened last year, but what’re folks thoughts on what happened to the prior CEO? I only ask because I see that she has quite a large amount of shares (3.1m). She hasn’t sold any since 2/2024 (I assume there is likely a clause in her exit contract that prevents her from selling for a certain amount of time). If anyone is in the weeds here, please share. Otherwise, I really like the focus and programs that this company is advancing. Bispecifics are a hot area and this company appears to be moving along quite well with a very strong/competent BOD supporting them.

0 · Reply

AvalancheAlpha Aug. 23 at 9:28 AM

$CMPX Compass Therapeutics Inc is a clinical stage immuno-oncology company with antibody platform

0 · Reply

redistributeW Aug. 22 at 4:06 PM

$CMPX offering closed???

0 · Reply

lexlut Aug. 22 at 2:43 PM

$CMPX

0 · Reply

Doozio Aug. 22 at 1:00 PM

$CMPX scrabble bag $CMPS cuz yo already know it was always during 🐒🍌🧠⏰♾️

0 · Reply

Zobzork Aug. 21 at 4:59 PM

$CMPX small position

0 · Reply

King_of_Bio Aug. 21 at 1:58 PM

$GOSS $AKBA $TSHA $SLS $CMPX If you don't have at least one of these bio stocks in your portfolio - I suggest you do some research. Great opportunities here!

1 · Reply

lexlut Aug. 21 at 9:09 AM

$CMPX

0 · Reply

BigSqueezeComing Aug. 21 at 9:03 AM

$CMPX hot pm gappers

0 · Reply

lexlut Aug. 20 at 8:01 AM

$CMPX https://finance.yahoo.com/news/compass-therapeutics-cmpx-rated-outperform-042204428.html

0 · Reply

Market Cap	475.69M
Revenue (ttm)	850,000.00
Net Income (ttm)	-49.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,809.41%
Debt to Equity Ratio	0.00

Volume	388,800
Avg Vol	1,063,888
Day's Range	N/A - N/A
Shares Out	138.28M
Stochastic %K	73%
Beta	1.50
Analysts	Strong Sell
Price Target	$13.20